Catapult Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Catapult Capital Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	$1.65M	Sell	12,280 -9,294	-43%	-$1.34M	0.62%	51
2015 Q2	$3.25M	Sell	21,574 -15,608	-42%	-$2.23M	0.47%	67
2015 Q1	$5.03M	Buy	+37,182	New	+$4.61M	0.61%	48
2014 Q3	–	Sell	-14,597	Closed	-$1.75M	–	200
2014 Q2	$1.75M	Sell	14,597 -2,447	-14%	-$299K	0.2%	135
2014 Q1	$2.18M	Buy	+17,044	New	+$2.18M	0.44%	69
2013 Q3	–	Sell	-360	Closed	-$40K	–	244
2013 Q2	$40K	Buy	+360	New	+$42.2K	0.02%	221

Other funds holding BIO

ACM

Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

LCS

Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Catapult Capital Management's BIO Position: Q3 2015 in Review

Catapult Capital Management reduced its Bio-Rad Laboratories Class A (BIO) stake by 43% in Q3 2015, selling an estimated $1.34M and leaving 12,280 shares worth $1.65M. The position accounts for 0.62% of the portfolio, ranked #51.

Catapult Capital Management first reported a position in BIO in Q2 2013 and has held it in 6 quarters since. The position peaked at $5.03M in Q1 2015. 244 funds tracked by Wall St. Rank hold BIO as of Q3 2015.

Catapult Capital Management held 12,280 shares of Bio-Rad Laboratories Class A worth $1.65M as of Q3 2015.
Catapult Capital Management sold 9,294 Bio-Rad Laboratories Class A shares in Q3 2015, an estimated $1.34M.
Bio-Rad Laboratories Class A made up 0.62% of Catapult Capital Management's portfolio in Q3 2015, its #51 holding.
Catapult Capital Management first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and has held it in 6 quarters since.
Catapult Capital Management's Bio-Rad Laboratories Class A position peaked at $5.03M in Q1 2015.
244 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2015.

Based on Catapult Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.